HomeCompareXVIPY vs EPRT

XVIPY vs EPRT: Dividend Comparison 2026

XVIPY yields 30.58% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 XVIPY wins by $72.5K in total portfolio value
10 years
XVIPY
XVIPY
● Live price
30.58%
Share price
$6.54
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$136.9K
Annual income
$18,414.99
Full XVIPY calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — XVIPY vs EPRT

📍 XVIPY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodXVIPYEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, XVIPY + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
XVIPY pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

XVIPY
Annual income on $10K today (after 15% tax)
$2,599.39/yr
After 10yr DRIP, annual income (after tax)
$15,652.74/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, XVIPY beats the other by $4,457.52/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of XVIPY + EPRT for your $10,000?

XVIPY: 50%EPRT: 50%
100% EPRT50/50100% XVIPY
Portfolio after 10yr
$100.6K
Annual income
$15,792.93/yr
Blended yield
15.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

XVIPY
No analyst data
Altman Z
4.9
Piotroski
6/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

XVIPY buys
0
EPRT buys
0
No recent congressional trades found for XVIPY or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricXVIPYEPRT
Forward yield30.58%3.97%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$136.9K$64.3K
Annual income after 10y$18,414.99$13,170.85
Total dividends collected$94.1K$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: XVIPY vs EPRT ($10,000, DRIP)

YearXVIPY PortfolioXVIPY Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$13,758$3,058.10$11,212$512.01+$2.5KXVIPY
2$18,653$3,932.12$12,689$692.09+$6.0KXVIPY
3$24,941$4,982.42$14,521$944.30+$10.4KXVIPY
4$32,914$6,226.19$16,841$1,302.88+$16.1KXVIPY
5$42,896$7,678.77$19,841$1,821.64+$23.1KXVIPY
6$55,252$9,353.04$23,818$2,587.47+$31.4KXVIPY
7$70,379$11,258.95$29,230$3,744.65+$41.1KXVIPY
8$88,708$13,403.14$36,816$5,540.38+$51.9KXVIPY
9$110,707$15,788.69$47,806$8,413.17+$62.9KXVIPY
10$136,871$18,414.99$64,324$13,170.85+$72.5KXVIPY

XVIPY vs EPRT: Complete Analysis 2026

XVIPYStock

Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.

Full XVIPY Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this XVIPY vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

XVIPY vs SCHDXVIPY vs JEPIXVIPY vs OXVIPY vs KOXVIPY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.